VIVUS (VVUS) Trading Up 6%

Shares of VIVUS, Inc. (NASDAQ:VVUS) were up 6% during trading on Thursday . The company traded as high as $0.53 and last traded at $0.53. Approximately 535,180 shares were traded during mid-day trading, an increase of 13% from the average daily volume of 474,598 shares. The stock had previously closed at $0.50.

A number of analysts have recently commented on VVUS shares. ValuEngine upgraded VIVUS from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Zacks Investment Research downgraded VIVUS from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th.

The stock has a market capitalization of $53.21, a PE ratio of 1.61 and a beta of 0.80. The company has a debt-to-equity ratio of 643.86, a current ratio of 7.47 and a quick ratio of 7.09.

VIVUS (NASDAQ:VVUS) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07. The company had revenue of $15.19 million for the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. VIVUS’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.09) earnings per share. sell-side analysts expect that VIVUS, Inc. will post -0.32 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. IHT Wealth Management LLC boosted its position in VIVUS by 653.3% during the second quarter. IHT Wealth Management LLC now owns 1,130 shares of the biopharmaceutical company’s stock worth $1,100,000 after purchasing an additional 980 shares in the last quarter. Bank of New York Mellon Corp boosted its position in VIVUS by 7.2% during the second quarter. Bank of New York Mellon Corp now owns 114,564 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 7,722 shares in the last quarter. Northern Trust Corp boosted its position in VIVUS by 16.8% during the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 39,473 shares in the last quarter. Russell Investments Group Ltd. boosted its position in VIVUS by 84.8% during the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 68,200 shares in the last quarter. Finally, OxFORD Asset Management LLP boosted its position in VIVUS by 14.0% during the third quarter. OxFORD Asset Management LLP now owns 1,059,382 shares of the biopharmaceutical company’s stock worth $1,040,000 after purchasing an additional 129,871 shares in the last quarter. Institutional investors own 31.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “VIVUS (VVUS) Trading Up 6%” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/12/vivus-vvus-trading-up-6.html.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit